Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
The long serum t1/2 of IgGs is ensured by their interaction with the neonatal Fc receptor (FcRn), which salvages IgG from intracellular degradation. Fc glycosylation is thought not to influence FcRn binding and IgG longevity in vivo. In this article, we demonstrate that hypersialylation of asparagine 297 (N297) enhances IgG serum persistence. This polarized glycosylation is achieved using a novel Fc mutation, a glutamate residue deletion at position 294 (Del) that endows IgGs with an up to 9-fold increase in serum lifespan. The strongest impact was observed when the Del was combined with Fc mutations improving FcRn binding (Del-FcRn+). Enzymatic desialylation of a Del-FcRn+ mutant or its production in a cell line unable to hypersialylate reduced the in vivo serum t1/2 of the desialylated mutants to that of native FcRn+ mutants. Consequently, our study proves that sialylation of the N297 sugar moiety has a direct impact on human IgG serum persistence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is beneficial as more sialylated glycoforms have been shown to have a longer in vivo half‐life. 38 , 39”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [39]
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229 · cited 4×
“This medicinal prospect became reality with the advent of immortalization of Ab-producing clonal B cells following their somatic cell fusion with myeloma cells (2).”
BackgroundMethodInfluentialFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Carbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914 · cited 2×
“acid on galactose residues masks the epitope, thereby inhibiting their removal from circulation (62).”
BackgroundCartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“ably because the IgG low-fucose content already resulted in high binding to this receptor, reducing the additional impact of the mutations (15).”
BackgroundAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Self-citationPaul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457 · cited 1×
“Two assays were set up to characterize the interaction of the IgG variants with hFcRn: 1) biolayer interferometry (BLI) and 2) competitive binding assay on FcRn-expressing Jurkat cells (1).”
MethodThe Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“To eliminate sialylated residues from glycans, the IgG variant T5A-74Del was treated with sialidase A (GK80040; Prozyme) to release a(2,3)-, a(2,6)-, a(2,8)-, and a(2,9)-linked N-acetylneuraminic acid.”
Method
Cited by
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
“The collection of mutations were studied as individual mutations to elucidate the function of the deletion of Glu294 (115).”
BackgroundInfluentialConsiderations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
The history of IgG glycosylation and where we are now
Cobb, B. A. (2020) · Glycobiology · doi:10.1093/glycob/cwz065 · Cited by 193
“Indeed, Fc sialylation increases circulatory half-life of antibodies (Bas et al. 2019), likely by avoiding ligation by both the asialoglycoprotein receptor (ASGPR) in the liver and the neonatal Fc receptor FcRn.”
BackgroundThe Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
“that hypersialylation of N297 is able to extend the half-life of IgG [170].”
BackgroundImpact of structural modifications of IgG antibodies on effector functions
Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 123
Metadata
- Authors
- Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., Mondon, P., Fournier, N., de Romeuf, C., Jorieux, S., Fontayne, A., Mars, L. T., & Monnet, C.
- Affiliations
- Inserm (FR)
- LFB (France) (FR)
- LFB Biotechnologies , 91958 Courtaboeuf Cedex ,
- LFB Biotechnologies , 59011 Lille Cedex ,
- Corresponding author
- Bas, Mathilde
- Dupont, Gilles
- Mondon, Philippe
- Fournier, Nathalie
- Jorieux, Sylvie
- Fontayne, Alexandre
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03-01
- Volume
- 202
- Issue
- 5
- Pages
- 1582-1594
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2912324466
- Cited by
- 82
- References
- 84
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 13 · 2020: 10 · 2019: 8
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-17-CE15-0028)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- neonatal Fc receptor, Fc glycosylation, FcRn binding, therapeutic antibodies, desialylation, antibody persistence
- MeSH terms
- Animals, Antibodies, Half-Life, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Mice, Knockout, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies. https://app.cochat.ai/papers/10.4049/jimmunol.1800896
- The paper
- Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., Mondon, P., Fournier, N., de Romeuf, C., Jorieux, S., Fontayne, A., Mars, L. T., & Monnet, C. (2019). Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1800896
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.